Dr. Dima AbdulJabbar continues to strengthen her commitment to evidence-based oncology through participation in leading international scientific meetings. As part of this commitment, she attended the ASCO Annual Meeting 2026, one of the world’s largest and most influential oncology conferences, bringing together more than 40,000 oncologists, researchers, healthcare professionals, and industry leaders from around the globe.

Organized annually by the American Society of Clinical Oncology (ASCO), the meeting serves as a premier international platform for presenting groundbreaking clinical research, discussing advances in cancer diagnosis and treatment, and shaping the future of oncology through scientific collaboration and innovation. The 2026 meeting featured more than 7,000 scientific abstracts, highlighting the rapid pace of progress across virtually every field of cancer care.

Among the most significant scientific highlights presented during ASCO 2026 were advances that have the potential to influence future standards of cancer treatment. One of the most closely watched presentations introduced encouraging Phase III data for daraxonrasib, an investigational targeted therapy for advanced pancreatic cancer, demonstrating improved survival outcomes and renewed hope for one of the most challenging cancers to treat.

The conference also showcased important progress in breast cancer treatment, with new evidence supporting expanded use of HER2-targeted therapies, including trastuzumab deruxtecan (Enhertu) in selected patient populations. Researchers presented additional data aimed at improving outcomes through earlier intervention and more personalized treatment strategies.

Another major focus of ASCO 2026 was the continued evolution of Precision Oncology, where genomic profiling and biomarker-driven treatment selection are transforming the way cancer is diagnosed and managed. Advances in molecular testing are allowing physicians to identify therapies that are tailored to the unique characteristics of each patient’s tumor, helping improve treatment effectiveness while minimizing unnecessary therapies.

In addition, experts presented new developments in immunotherapy, targeted therapies, supportive care, cancer prevention, survivorship, and quality-of-life research, reflecting the growing emphasis on delivering more personalized, effective, and patient-centered cancer care.

For Dr. Dima AbdulJabbar, participation in international scientific meetings represents an essential part of continuous professional development. Staying connected with the latest clinical evidence, emerging technologies, and global advances in oncology reinforces her commitment to providing patients with care that reflects the highest international standards and the latest evidence-based treatment approaches.